Skip to main content

Advertisement

SpringerLink
Log in

Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions

  • Echocardiography (JM Gardin, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

A commonly encountered scenario is the patient with atrial fibrillation (AF) on oral anticoagulation (OAC) who either develops an acute coronary syndrome or has to undergo percutaneous coronary intervention with stent placement. In such patients, separate indications suggest combining OAC and dual antiplatelet therapy (DAPT). This approach, however, increases the risk of bleeding as well as thromboembolic risk if bleeding does not occur. For optimal clinical results, the risks and benefits of all possible treatment options should be determined based on the best available data. This review provides an overview of the most recent data regarding the optimal treatment of AF patients with an indication for combined treatment with OAC and DAPT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.

    Article  CAS  PubMed  Google Scholar 

  2. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost. 2010;103:13–28.

    Article  CAS  PubMed  Google Scholar 

  3. Connolly S, Pogue J, Hart R, et al. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–78.

    Article  PubMed  Google Scholar 

  4. Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–12.

    Article  CAS  PubMed  Google Scholar 

  5. Flaker GC, Gruber M, Connolly SJ, et al. SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152(5):967–73.

    Article  CAS  PubMed  Google Scholar 

  6. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–8.

    Article  PubMed  Google Scholar 

  7. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:CD006186.

    PubMed  Google Scholar 

  8. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2007;146:204–10.

    Article  PubMed  Google Scholar 

  9. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.

    Article  PubMed  Google Scholar 

  10. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381–91.

    Article  CAS  PubMed  Google Scholar 

  11. Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2013;167(4):1237–41.

    Article  PubMed  Google Scholar 

  12. Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circulation. 2012;5:357–64.

    CAS  PubMed  Google Scholar 

  13. Valgimigli M, Tebaldi M, Borghesi M, et al. Prodigy Investigators: Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2014;7(1):20–8.

    Article  PubMed  Google Scholar 

  14. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084–9.

    Article  PubMed  Google Scholar 

  15. Grines CL, Bonow RO, Casey Jr DE, et al. American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813–8.

    Article  PubMed  Google Scholar 

  16. Yusuf S, Zhao F, Mehta SR, et al. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  CAS  PubMed  Google Scholar 

  17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–16.

    Article  CAS  PubMed  Google Scholar 

  18. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  CAS  PubMed  Google Scholar 

  19. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    Article  CAS  PubMed  Google Scholar 

  20. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2012;79:453–95.

    Article  PubMed  Google Scholar 

  21. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362–425.

    Article  PubMed  Google Scholar 

  22. Verheugt FW. Low-dose anticoagulation for secondary prevention in acute coronary syndrome. Am J Cardiol. 2013;111(4):618–26.

    Article  CAS  PubMed  Google Scholar 

  23. van Werkum J, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis. The Dutch stent thrombosis registry. J Am Coll Cardiol. 2009;53:1399–409.

    Article  PubMed  Google Scholar 

  24. Hamm CW, Bassand JP, Agewall S, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.

    Article  PubMed  Google Scholar 

  25. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost. 2010;103:13–28.

    Article  CAS  PubMed  Google Scholar 

  26. Kralev S, Schneider K, Lang S, et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011;6(9):e24964.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Ruff CT, Bhatt DL, Steg PG, et al. REACH Registry Investigators. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014;170(3):413–8.

    Article  PubMed  Google Scholar 

  28. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011;106:572–84.

    Article  CAS  PubMed  Google Scholar 

  29. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.

    Article  CAS  PubMed  Google Scholar 

  30. Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121:2067–70.

    Article  PubMed  Google Scholar 

  31. Rubboli A, Milandri M, Castelvetri C, et al. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology. 2005;104:101–6.

    Article  PubMed  Google Scholar 

  32. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185–93.

    Article  PubMed  Google Scholar 

  33. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40:428–36.

    Article  CAS  PubMed  Google Scholar 

  34. Lip GY, Huber K, Andreotti F, et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103:13–28.

    Article  CAS  PubMed  Google Scholar 

  35. European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:1360–420.

    Google Scholar 

  36. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011;106:572–84.

    Article  CAS  PubMed  Google Scholar 

  37. Bennaghmouch N, Sprenkeler D, Qaderdan K, ten Berg JM. Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation. J Cardiovasc Transl Res. 2014;7(1):64–71.

    Article  CAS  PubMed  Google Scholar 

  38. Gao F, Zhou YJ, Wang ZJ, et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol. 2011;148:96–101.

    Article  PubMed  Google Scholar 

  39. Zhao HJ, Zheng ZT, Wang ZH, et al. “Triple therapy” rather than “triple threat”: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest. 2011;139:260–70.

    Article  PubMed  Google Scholar 

  40. Singh PP, Singh M, Bedi U, et al. Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. Ther Adv Cardiovasc Dis. 2011;5:23–31.

    Article  PubMed  Google Scholar 

  41. Andrade JG, Deyell MW, Khoo C, et al. Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis. Can J Cardiol. 2013;29:204–12.

    Article  PubMed  Google Scholar 

  42. Saheb KJ, Deng BQ, Hu QS, et al. Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis. Chin Med J (Engl). 2013;126:2536–42.

    Google Scholar 

  43. Smith JG, Wieloch M, Koul S, et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention. 2012;8(6):672–8.

    Article  PubMed  Google Scholar 

  44. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41. This is one of the first studies reporting the bleeding hazards associated with triple therapy as found in a very large cohort.

    Article  CAS  PubMed  Google Scholar 

  45. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28(6):726–32.

    Article  CAS  PubMed  Google Scholar 

  46. Rubboli A, Schlitt A, Kiviniemi T; for the AFCAS Study Group. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS Registry. Clin Cardiol. 2014 Jan 30.

  47. Lip GY, Andreotti F, Fauchier L, et al. for the European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997–1011.

    Article  CAS  PubMed  Google Scholar 

  48. Skanes AC, Healey JS, Cairns JA, et al. for the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian cardiovascular society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125–36.

    Article  PubMed  Google Scholar 

  49. Kiviniemi T, Puurunen M, Schlitt A, et al. Performance of bleeding risk-prediction scores in patients with atrial fibrillation undergoing percutaneous coronary intervention. JACC, E-pub 1 April 2014.

  50. Jolly SS, Amlani S, Hamon M, et al. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J. 2009;157:132–40.

    Article  PubMed  Google Scholar 

  51. Jolly SS, Yusuf S, Cairns J, et al. RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409–20.

    Article  PubMed  Google Scholar 

  52. Ziakas AG, Koskinas KC, Gavrilidis S, et al. Radial versus femoral access for orally anticoagulated patients. Catheter Cardiovasc Interv. 2010;76:493–9.

    Article  PubMed  Google Scholar 

  53. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57(11):1251–63.

    Article  CAS  PubMed  Google Scholar 

  54. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713–8.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Bhatt DL, Cryer BL, Contant CF, et al. COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.

    Article  CAS  PubMed  Google Scholar 

  56. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15. This is the first randomized trial in patients on chronic OAC and undergoing percutaneous coronary intervention investigating two antithrombotic strategies and providing evidence for dual antiplatelet therapy with clopidogrel and OAC without aspirin.

    Article  CAS  PubMed  Google Scholar 

  57. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62(11):981–9. This is a large cohort study reporting the benefits of dual therapy with clopidogrel and OAC without aspirin in daily care, providing more support for this new strategy.

    Article  CAS  PubMed  Google Scholar 

  58. Seivani Y, Abdel-Wahab M, Geist V, Richard T, et al. Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol. 2013;102(11):799–806.

    Article  CAS  PubMed  Google Scholar 

  59. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789–97.

    Article  CAS  PubMed  Google Scholar 

  60. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–85.

    Article  PubMed  Google Scholar 

  61. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29–38.

    Article  CAS  PubMed  Google Scholar 

  62. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781–9.

    Article  CAS  PubMed  Google Scholar 

  63. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.

    Article  CAS  PubMed  Google Scholar 

  65. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19. This is the only phase 3 trial reporting possible benefits of the combination of NOACs and antiplatelet therapy in patients with acute coronary syndrome.

    Article  CAS  PubMed  Google Scholar 

  66. Komocsi A, Vorobcsuk A, Kehl D, et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(20):1537–45.

    Article  PubMed  Google Scholar 

  67. Oldgren J, Wallentin L, Alexander JH, et al. “New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis”. Eur Heart J 2013 Mar (in press).

  68. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  69. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014.

  70. Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv. 2012;5(2):131–40.

    Article  PubMed  Google Scholar 

  71. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667–78.

    Article  CAS  PubMed  Google Scholar 

  72. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297(2):159–68.

    Article  CAS  PubMed  Google Scholar 

  73. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574–651.

    Article  PubMed  Google Scholar 

  74. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267–74.

    Article  PubMed  Google Scholar 

  75. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745–54.

    Article  CAS  PubMed  Google Scholar 

  76. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714–21.

    Article  CAS  PubMed  Google Scholar 

  77. Roy P, Bonello L, Torguson R, et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol. 2009;103(6):801–5.

    Article  CAS  PubMed  Google Scholar 

  78. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362(15):1374–82.

    Article  CAS  PubMed  Google Scholar 

  79. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505–13.

    Article  CAS  PubMed  Google Scholar 

  80. Valgimigli M, Campo G, Monti M, et al. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015–26.

    Article  CAS  PubMed  Google Scholar 

  81. Kim BK, Hong MK, Shin DH, et al. RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340–8.

    Article  CAS  PubMed  Google Scholar 

  82. Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J. 2012;33(24):3078–87. This is a meta-analysis of RCTs providing evidence that extending DAPT increases bleeding events without reducing ischaemic events.

    Article  CAS  PubMed  Google Scholar 

  83. Valgimigli M, Park SJ, Kim HS, et al. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials. Int J Cardiol. 2013;168(3):2579–87. This is an important meta-analysis reporting no benefits with longer DAPT duration as compared with a shorter course of therapy but significant harms with respect to major bleeding and stroke associated with prolonged DAPT use.

    Article  PubMed  Google Scholar 

  84. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510–22. This is the first RCT providing evidence for non-inferiority of 3 months of DAPT compared to 12 months without significantly increasing the risk of stent thrombosis.

    CAS  PubMed  Google Scholar 

  85. Risk-tailored DAPT boosts DES safety in difficult patient group. Medscape. Apr 03, 2014.

  86. ClinicalTrials.gov. Triple therapy in patients on oral anticoagulation after drug eluting stent implantation (ISAR-TRIPLE). Available at: http://clinicaltrials.gov/show/NCT00776633. [Last access at 5-5-2014].

  87. ClinicalTrials.gov. Anticoagulation in stent intervention (MUSICA-2). Available at: http://clinicaltrials.gov/show/NCT01141153 [Last access at 5-5-2014].

  88. ClinicalTrials.gov. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Available at: http://clinicaltrials.gov/show/NCT01830543. [Last access at 5-5-2014].

  89. “Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations”, RE-DUAL PCI. Available at: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/19_november_2013_dabigatranetexilate1.html. [Last access at 5-5-2014].

  90. ClinicalTrials.gov. Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirudin and biomatrix family drug-eluting stent use (GLOBAL LEADERS). Available at: http://clinicaltrials.gov/ct2/show/NCT01813435. [Last access at 5-5-2014].

  91. ClinicalTrials.gov. Safety and efficacy of six months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE). Available at: http://clinicaltrials.gov/show/NCT00661206. [Last access at 5-5-2014].

Download references

Compliance with Ethics Guidelines

Conflict of Interest

N. Bennaghmouch, W.J.M. Dewilde, and J.M. ten Berg declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with animal subjects performed by any of the authors. With regard to the authors’ research cited in this paper, all procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 and 2008.

Author information

Authors and Affiliations

  1. Department of Cardiology, St Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands

    N. Bennaghmouch & J. M. Ten Berg

  2. Department of Cardiology, Amphia Hospital Breda, Molengracht 21, 4818 CK, Breda, The Netherlands

    W. J. M. Dewilde

Authors
  1. N. Bennaghmouch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. J. M. Dewilde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. Ten Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Bennaghmouch.

Additional information

This article is part of the Topical Collection on Echocardiography

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bennaghmouch, N., Dewilde, W.J.M. & Ten Berg, J.M. Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions. Curr Cardiol Rep 16, 548 (2014). https://doi.org/10.1007/s11886-014-0548-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-014-0548-6

Keywords

Search

Navigation